William Grady

Dr. William Grady


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2015 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
YOYoshinaga Okugawa
Yoshinaga Okugawa
WGWilliam Grady
William Grady
AGAjay Goel
Ajay Goel

18 October 2011 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
PDF file
VLVictoria Valinluck Lao
Victoria Valinluck Lao
WGWilliam Grady
William Grady

31 May 2018 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
CGCatherine S. Grasso
Catherine S. Grasso
MGMarios Giannakis
Marios Giannakis
DWDaniel K. Wells
Daniel K. Wells
THTsuyoshi Hamada
Tsuyoshi Hamada
XMXinmeng Jasmine Mu
Xinmeng Jasmine Mu
UPUlrike Peters
Ulrike Peters
To understand the genetic drivers of immune recognition and evasion in colorectal cancer, we analyzed 1,211 colorectal cancer primary tumor samples, including 179 classified as microsatellite instability–high (MSI-high). This set includes The Cancer Genome Atlas colorectal cancer cohort of 592 samples, completed and analyzed here. MSI-high, a hypermutated, immunogenic subtype of colorectal cancer, had a high rate of significantly mutated genes in important immune-modulating pathways and in the antigen presentation machinery, including biallelic losses of B2M and HLA genes due to copy-number alterations and copy-neutral loss of heterozygosity. WNT/β-catenin signaling genes were significantly mutated in all colorectal cancer subtypes, and activated WNT/β-catenin signaling was correlated with the absence of T-cell infiltration. This large-scale genomic analysis of colorectal cancer demonstrates that MSI-high cases frequently undergo an immunoediting process that provides them with genetic events allowing immune escape despite high mutational load and frequent lymphocytic infiltration and, furthermore, that colorectal cancer tumors have genetic and methylation events associated with activated WNT signaling and T-cell exclusion. Significance: This multi-omic analysis of 1,211 colorectal cancer primary tumors reveals that it should be possible to better monitor resistance in the 15% of cases that respond to immune blockade therapy and also to use WNT signaling inhibitors to reverse immune exclusion in the 85% of cases that currently do not. Cancer Discov; 8(6); 730–49. ©2018 AACR. This article is highlighted in the In This Issue feature, p. 663

14 December 2021 in Cell
Verified
Journal Article
Open access
BCBob Chen
Bob Chen
CSCherie’ R. Scurrah
Cherie’ R. Scurrah
EMEliot T. McKinley
Eliot T. McKinley
ASAlan J. Simmons
Alan J. Simmons
MRMarisol A. Ramirez-Solano
Marisol A. Ramirez-Solano
KLKen S. Lau
Ken S. Lau
Colorectal cancers (CRCs) arise from precursor polyps whose cellular origins, molecular heterogeneity, and immunogenic potential may reveal diagnostic and therapeutic insights when analyzed at high resolution. We present a single-cell transcriptomic and imaging atlas of the two most common human colorectal polyps, conventional adenomas and serrated polyps, and their resulting CRC counterparts. Integrative analysis of 128 datasets from 62 participants reveals adenomas arise from WNT-driven expansion of stem cells, while serrated polyps derive from differentiated cells through gastric metaplasia. Metaplasia-associated damage is coupled to a cytotoxic immune microenvironment preceding hypermutation, driven partly by antigen-presentation differences associated with tumor cell-differentiation status. Microsatellite unstable CRCs contain distinct non-metaplastic regions where tumor cells acquire stem cell properties and cytotoxic immune cells are depleted. Our multi-omic atlas provides insights into malignant progression of colorectal polyps and their microenvironment, serving as a framework for precision surveillance and prevention of CRC.

4 October 2010 in Gut
Verified
Journal Article
Open access
PDF file
CPColin C Pritchard
Colin C Pritchard
WGWilliam Grady
William Grady
The promise of personalised medicine is now a clinical reality, with colorectal cancer genetics at the forefront of this next major advance in clinical medicine. This is no more evident than in the recent advances in testing of colorectal cancers for specific molecular alterations in order to guide treatment with the monoclonal antibody therapies cetuximab and panitumumab, which target the epidermal growth factor receptor. In this review, genetic mechanisms of colorectal cancer and how these alterations relate to emerging biomarkers for early detection and risk stratification (diagnostic markers), prognosis (prognostic markers) and the prediction of treatment responses (predictive markers) are examined.

3 December 2020 in Gastroenterology
Verified
Journal Article
Closed access
WGWilliam Grady
William Grady
MYMing Yu
Ming Yu
SMSanford D. Markowitz
Sanford D. Markowitz